FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213073516> ?p ?o ?g. }

• W4213073516 endingPage "958" @default.
• W4213073516 startingPage "949" @default.
• W4213073516 abstract "Evidence of neoadjuvant chemoimmunotherapy for locally advanced non-small cell lung cancer remains investigational and requires prospective validation. This phase II trial (https://www.chictr.org.cn/historyversionpub.aspx?regno=ChiCTR1900023758) aimed to investigate the safety and effectiveness of neoadjuvant PD-1 inhibitor sintilimab in addition to chemotherapy in the management of resectable stage IIIA non-small cell lung cancer.Eligible patients received two to four 21-day cycles of neoadjuvant therapy: sintilimab (200 mg) and carboplatin (area under the curve 5) on day 1, gemcitabine (1000 mg/m2) on day 1 and day 8 for squamous cell carcinoma, or pemetrexed (500 mg/m2) on day 1 for adenocarcinoma and non-small cell lung cancer not otherwise specified. The primary endpoints were adverse events and major pathological response. The secondary endpoint was disease-free survival at 1 year.Fifty patients were enrolled, and 23 (46%) achieved partial response after neoadjuvant chemoimmunotherapy. Four (8%) patients experienced grade 3 to 5 adverse events. Thirty patients received surgery, none of whom experienced treatment-related surgery delays, and 13 (43.3%) of 30 patients achieved major pathological response (viable tumor ≤10%). With a median follow-up of 13.6 months, 85.3% of patients were disease-free at 1 year (N = 50).Neoadjuvant sintilimab with platinum-containing dual-agent chemotherapy was feasible and safe for patients with resectable stage IIIA non-small cell lung cancer." @default.
• W4213073516 created "2022-02-24" @default.
• W4213073516 creator A5013236440 @default.
• W4213073516 creator A5021443137 @default.
• W4213073516 creator A5021964629 @default.
• W4213073516 creator A5022497084 @default.
• W4213073516 creator A5022621937 @default.
• W4213073516 creator A5028340973 @default.
• W4213073516 creator A5029360035 @default.
• W4213073516 creator A5042976629 @default.
• W4213073516 creator A5043602308 @default.
• W4213073516 creator A5087800686 @default.
• W4213073516 date "2022-09-01" @default.
• W4213073516 modified "2023-10-17" @default.
• W4213073516 title "Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer" @default.
• W4213073516 cites W2038716687 @default.
• W4213073516 cites W2106213702 @default.
• W4213073516 cites W2109567704 @default.
• W4213073516 cites W2117994949 @default.
• W4213073516 cites W2134291074 @default.
• W4213073516 cites W2157105206 @default.
• W4213073516 cites W2166281097 @default.
• W4213073516 cites W2182482244 @default.
• W4213073516 cites W2468576628 @default.
• W4213073516 cites W2609444947 @default.
• W4213073516 cites W2635951006 @default.
• W4213073516 cites W2891486030 @default.
• W4213073516 cites W2967520916 @default.
• W4213073516 cites W2981322953 @default.
• W4213073516 cites W2982617740 @default.
• W4213073516 cites W2990814876 @default.
• W4213073516 cites W2995986038 @default.
• W4213073516 cites W3005124847 @default.
• W4213073516 cites W3009701405 @default.
• W4213073516 cites W3021010739 @default.
• W4213073516 cites W3033779930 @default.
• W4213073516 cites W3041284694 @default.
• W4213073516 cites W3046923728 @default.
• W4213073516 cites W3089266118 @default.
• W4213073516 cites W4292994367 @default.
• W4213073516 doi "https://doi.org/10.1016/j.athoracsur.2022.01.039" @default.
• W4213073516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35176262" @default.
• W4213073516 hasPublicationYear "2022" @default.
• W4213073516 type Work @default.
• W4213073516 citedByCount "17" @default.
• W4213073516 countsByYear W42130735162021 @default.
• W4213073516 countsByYear W42130735162022 @default.
• W4213073516 countsByYear W42130735162023 @default.
• W4213073516 crossrefType "journal-article" @default.
• W4213073516 hasAuthorship W4213073516A5013236440 @default.
• W4213073516 hasAuthorship W4213073516A5021443137 @default.
• W4213073516 hasAuthorship W4213073516A5021964629 @default.
• W4213073516 hasAuthorship W4213073516A5022497084 @default.
• W4213073516 hasAuthorship W4213073516A5022621937 @default.
• W4213073516 hasAuthorship W4213073516A5028340973 @default.
• W4213073516 hasAuthorship W4213073516A5029360035 @default.
• W4213073516 hasAuthorship W4213073516A5042976629 @default.
• W4213073516 hasAuthorship W4213073516A5043602308 @default.
• W4213073516 hasAuthorship W4213073516A5087800686 @default.
• W4213073516 hasConcept C121608353 @default.
• W4213073516 hasConcept C126322002 @default.
• W4213073516 hasConcept C141071460 @default.
• W4213073516 hasConcept C143998085 @default.
• W4213073516 hasConcept C197934379 @default.
• W4213073516 hasConcept C203092338 @default.
• W4213073516 hasConcept C2776256026 @default.
• W4213073516 hasConcept C2776694085 @default.
• W4213073516 hasConcept C2776755627 @default.
• W4213073516 hasConcept C2777240266 @default.
• W4213073516 hasConcept C2778239845 @default.
• W4213073516 hasConcept C2778292576 @default.
• W4213073516 hasConcept C2780258809 @default.
• W4213073516 hasConcept C2780790343 @default.
• W4213073516 hasConcept C2781182431 @default.
• W4213073516 hasConcept C2781451048 @default.
• W4213073516 hasConcept C530470458 @default.
• W4213073516 hasConcept C535046627 @default.
• W4213073516 hasConcept C71924100 @default.
• W4213073516 hasConceptScore W4213073516C121608353 @default.
• W4213073516 hasConceptScore W4213073516C126322002 @default.
• W4213073516 hasConceptScore W4213073516C141071460 @default.
• W4213073516 hasConceptScore W4213073516C143998085 @default.
• W4213073516 hasConceptScore W4213073516C197934379 @default.
• W4213073516 hasConceptScore W4213073516C203092338 @default.
• W4213073516 hasConceptScore W4213073516C2776256026 @default.
• W4213073516 hasConceptScore W4213073516C2776694085 @default.
• W4213073516 hasConceptScore W4213073516C2776755627 @default.
• W4213073516 hasConceptScore W4213073516C2777240266 @default.
• W4213073516 hasConceptScore W4213073516C2778239845 @default.
• W4213073516 hasConceptScore W4213073516C2778292576 @default.
• W4213073516 hasConceptScore W4213073516C2780258809 @default.
• W4213073516 hasConceptScore W4213073516C2780790343 @default.
• W4213073516 hasConceptScore W4213073516C2781182431 @default.
• W4213073516 hasConceptScore W4213073516C2781451048 @default.
• W4213073516 hasConceptScore W4213073516C530470458 @default.
• W4213073516 hasConceptScore W4213073516C535046627 @default.
• W4213073516 hasConceptScore W4213073516C71924100 @default.
• W4213073516 hasFunder F4320317608 @default.

• next